Arcus biosciences stock.

Arcus Biosciences and Gilead have decided not to advance their A2R inhibitor in prostate cancer after taking a look at some early clinical data.Arcus Biosciences, Inc. Common Stock (RCUS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s share price fell 3.7% during mid-day trading on Friday .The stock traded as low as $14.45 and last traded at $14.50. 19,641 shares were ...Nov 7, 2023 · Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently up 4.71% so far this month. During the month of November, Arcus Biosciences Inc’s stock price has reached a high of $16.76 and a low of $15.35. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $14.33. Year to date ... Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price targe...

Arcus Biosciences’ stock has declined 32.7% in the past year. Earnings of RCUS beat estimates in two of the last four quarters, missed the mark on one occasion and met the mark on another.

While ratings are subjective and will change, the latest Arcus Biosciences ( RCUS) rating was a maintained with a price target of $46.00 to $36.00. The current price Arcus Biosciences ( RCUS) is ...Nov 27, 2023 · Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 12,600 shares of the Company’s common stock at an exercise price ...

Arcus Biosciences last posted its quarterly earnings results on November 7th, 2023. The reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.18. The firm earned $32 million during the quarter, compared to analysts' expectations of $27.57 million. Its revenue for the quarter was down 3.0% on a year-over …Is Arcus Biosciences (NYSE:RCUS) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, pricing and company ...Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced seven accepted abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be …Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price ...According to 5 analyst offering 12-month price targets in the last 3 months, Arcus Biosciences has an average price target of $38.0 with a high of $42.00 and a low of $33.00.

Phase 1/1b results for the etrumadenant combination demonstrated a 4.2 month PFS, approximately double the 2 months reported for current standard of care therapies in the ≥3L mCRC setting ARC-9, a randomized Phase 1b/2 platform study, has been initiated to further evaluate etrumadenant-zimberelimab combinations in the 2L, 3L …

Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently up 4.71% so far this month. During the month of November, Arcus Biosciences Inc’s stock price has reached a high of $16.76 and a low of $15.35. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $14.33. Year to date ...

15 сак 2018 г. ... Hayward biopharmaceutical company Arcus Biosciences went public Thursday, with its stock rising 13 percent from its initial offer price of ...Arcus Biosciences-stock Arcus Biosciences Inc Registered Shs Stock , RCUS 14.34 +0.46 +3.35% 01:55:56 PM EDT 11/24/2023 NYSE Add to watchlist 13.88 …Get the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. See the current price, performance outlook, earnings date, dividend yield, fair value and more. Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today. 502%. Motley Fool Returns. Market-beating stocks from our award-winning analyst team. Stock Advisor Returns. 502% .Description. Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. HAYWARD, Calif., January 24, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences ( RCUS – Research Report) today and set a price target of $51.00. The company’s shares opened today at $19 ...

Exelixis, Inc. (EXEL) and Arcus Biosciences (RCUS) have announced a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis' next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, …Investigating Combination Therapies to Treat Cancer. Learn how cancer biology is guiding the study of potential, new combination medicines to treat specific types of cancer. Read More. Arcus is a biopharmaceutical company aiming to bring together scientists, physicians & advisors to focus on developing best-in-class cancer therapies. According to analysts' consensus price target of $43.13, Arcus Biosciences has a forecasted upside of 168.4% from its current price of $16.07. Amount of Analyst ...Track Arcus Biosciences Inc (RCUS) Stock Price, Quote, latest community messages, chart, news and other stock related information.RCUS POWR Grades. Value is the dimension where RCUS ranks best; there it ranks ahead of 69.33% of US stocks. RCUS's strongest trending metric is Quality; ...Arcus Biosciences and Gilead have decided not to advance their A2R inhibitor in prostate cancer after taking a look at some early clinical data.

15 мая 2023 г. ... Gilead is paying $35 million cash to expand an existing oncology partnership with Arcus Biosciences into inflammatory diseases.

Arcus Biosciences has raised a total of. $647.1M. in funding over 5 rounds. Their latest funding was raised on Feb 1, 2021 from a Post-IPO Equity round. Arcus Biosciences is registered under the ticker NYSE:RCUS . Their stock opened with $15.00 in its Mar 14, 2018 IPO. Arcus Biosciences is funded by 18 investors.Nov 22, 2023 · Arcus Biosciences stock has received a consensus rating of buy. The average rating score is and is based on 19 buy ratings, 3 hold ratings, and 0 sell ratings. What was the 52-week low for Arcus ... ARCUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware : 001 ... pursuant to which Gilead will make an upfront equity investment of $200 million by purchasing from Arcus 5,963,029 shares of Arcus common stock at a purchase price of $33.54 per share (the “Initial Purchase Price”). Gilead ...High levels of adenosine present in the tumor microenvironment have direct immunosuppressive impact on T-cell function and activation. AB928, a selective, small-molecule dual A2aR/A2bR antagonist, potently blocks the effects of adenosine and, in combination with chemotherapy or anti-PD-1, may have a more profound effect on …Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today. 502%. Motley Fool Returns. Market-beating stocks from our award-winning analyst team. Stock Advisor Returns. 502% .Arcus Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 32 million compared to USD 33 million a year ago.Sell candidate since Nov 09, 2023 Gain 2.33% PDF. No changes to the price of Arcus Biosciences Inc. stock on the last trading day (Monday, 27th Nov 2023). During the last trading day the stock fluctuated 4.63% from a day low at $13.50 to a day high of $14.12. The price has risen in 5 of the last 10 days and is up by 3.84% over the past 2 weeks.Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s share price fell 3.7% during mid-day trading on Friday .The stock traded as low as $14.45 and last traded at $14.50. 19,641 shares were ...Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with Gilead, Roche/Genentech, and AstraZeneca, and ...

Which technical analysis tools can be used to analyze Arcus Biosciences, Inc.? Check out various oscillators, moving averages and other technical indicators ...

Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today. 502%. Motley Fool Returns. Market-beating stocks from our award-winning analyst team. Stock Advisor Returns. 502% .

13 вер 2023 г. ... Arcus Biosciences Inc (RCUS) stock is trading at $21.32 as of 11:53 AM on Wednesday, Sep 13, a gain of $0.09, or 0.42% from the previous closing ...At the end of December 2022, Arcus Biosciences had cash, cash equivalents, and marketable securities totaling $1.1 billion; this was a significant increase from the $681 million at the end of 2021 ...US03969F1093. Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and …Arcus Biosciences, Inc. Appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...Calendar Arcus Biosciences, Inc. Equities. RCUS. US03969F1093. Market Closed - Nyse. Other stock markets.Arcus Biosciences, Inc.'s latest quarterly earnings per share is $-0.94 with a past EPS surprise of $0.18. The latest EPS estimate is $-1.02. Read more about ...Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced seven accepted abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be …According to 5 analyst offering 12-month price targets in the last 3 months, Arcus Biosciences has an average price target of $38.0 with a high of $42.00 and a low of $33.00.HAYWARD, Calif., January 10, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today. 502%. Motley Fool Returns. Market-beating stocks from our award-winning analyst team. Stock Advisor Returns. 502% .What happened. Shares of Arcus Biosciences (RCUS 6.71%) jumped by as much as 21% in premarket trading Thursday morning. The biotech's stock is heating up in early morning action today on the news ...This transaction with Arcus is expected to reduce Gilead’s GAAP and non-GAAP 2023 EPS by $0.02. About Arcus Biosciences. Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer.

Arcus Biosciences is a biopharmaceutical company that focuses on creating innovative cancer immunotherapies. The stock price, earnings, news, and research reports for RCUS are available on Zacks. See the latest updates on the company's product portfolio, performance, and outlook.Arcus Biosciences beat estimated earnings by 17.54%, reporting an EPS of $-0.94 versus an estimate of $-1.14. Revenue was down $1.58 million from the same period last year. Past Earnings PerformanceInvesting in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Instagram:https://instagram. best trading platform for index fundsglaifsafe growth stocksvdc etf Arcus Biosciences Stock Performance. Shares of RCUS opened at $14.05 on Tuesday. Arcus Biosciences, Inc. has a 12-month low of $12.95 and a 12-month high of $36.13. The company’s 50 day simple ...Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced seven accepted abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be … annuity payout ratesford ex dividend date Dec 24, 2022 · HAYWARD, Calif., December 24, 2022 -- ( BUSINESS WIRE )--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today ... carvana stok Arcus Biosciences, Inc. (NYSE: RCUS) was in 27 hedge funds' portfolios at the end of March. The all time high for this statistic is 31. RCUS has experienced a decrease in enthusiasm from smart ...In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $51.00.The company’s shares ...Description. Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates.